



Research article

Experimentally Induced Liver Cirrhosis with Ascites by Carbon Tetrachloride and Phenobarbital Sodium in Wistar Rats

Saravanan Mani^{1*}, Debratra Mondal², Kalyan Sarma³, Karampal Singh⁴

¹Teaching Veterinary Clinical Complex, VCRI Orathanadu, Thanjavur – 614625; ²Division of Medicine, Indian Veterinary research Institute, Izatnagr, Bareilly – 243 122 (UP) India; ³Department of Veterinary Medicine, College of Veterinary Sciences & A.H. Central Agricultural University, Selesih, Aizawl, Mizoram; ⁴Joint Directorate CADRAD, Indian Veterinary research Institute, Izatnagr, Bareilly – 243 122 (UP)

*Corresponding author: sara82vet@yahoo.com

ARTICLE HISTORY

Received: 2014-01-12
Revised: 2014-01-31
Accepted: 2014-01-31

ABSTRACT

The study was conducted to evaluate liver cirrhosis with ascites by Carbon tetrachloride and Phenobarbital sodium in rat model. Phenobarbital sodium @ 0.3g/L in the drinking water for first week followed by Carbon tetrachloride (CCl₄) along with olive oil (1:1 v/v) @ 2 ml per kg. B.wt was administered orally twice a week for 11 weeks. Reduction in Hb, PCV, TEC, TP, albumin, globulin and AG ratio while increased levels of TLC, total bilirubin, AST, ALT, and ALP were recorded. Estimation of oxidative stress indices revealed increased level of LPO along with decreased GSH, SOD and CAT. Liver showed severe fibrosis with cirrhotic nodule and 67% of rats were developed ascites. Carbon tetrachloride with Phenobarbital sodium can be used to induce hepatotoxicity (i.e. liver cirrhosis) with ascites in rat model.

All copyrights reserved to Nexus® academic publishers

ARTICLE CITATION: Mani S, Mondal D, Sarma K, Singh K (2014). Experimentally induced liver cirrhosis with ascites by carbon tetrachloride and Phenobarbital sodium in Wistar rats. Adv. Anim. Vet. Sci. 2 (3): 159 – 163.

INTRODUCTION

Liver plays vital role in human as well as animal body and it is the principal site for intense metabolism and excretion. It has a surprising role in the maintenance, performance and regulating homeostasis of the body. Liver involved with almost all the biochemical pathways to growth, fight against disease, nutrient supply, energy provision and reproduction (Ward and Daly, 1990). Ascites is the most common major complication of liver cirrhosis. Ascites is associated with poor quality of life, increased risk of infection, and renal failure (Runyon, 2004). The most validated cirrhosis model in the rat is produced with the use of the carbon tetrachloride (CCl₄) along with Phenobarbital sodium (Proctor and Chatamra, 1984).

Carbon tetrachloride (CCl₄) intoxication is a well-known model for producing oxidative stress and hepatic injury. Its biotransformation produces hepatotoxic metabolites, the highly reactive trichloromethyl free radical, which is further converted to the peroxytrichloromethyl radical (Williams and Burk, 1990). Reactive oxidant species may contribute to both onset and progression of fibrosis (Poli, 2000; Parola and Robino, 2001).

Many protocols exist, which differ in the route of administration (gavage, intra-peritoneal or subcutaneous injection), the dilution of CCl₄ (1/20 to 1/10), the frequency (1 to 4 wk) and the duration (8 to 28 wk) of CCl₄ administration. The efficiency of these protocols (70% to 100%), as well as the inherent toxic-mortality (20% to 90%) is variable in the literature (Mullen and McCullough, 1989). CCl₄ protocol for cirrhosis is best described by various research workers (Doi et al., 1991; Abroades et al., 2006). Hence, the study was intended to develop ascites of

hepato-biliary disorder in rat model by CCl₄ and Phenobarbital sodium.

MATERIALS AND METHODS

Experimental Model

Eighteen Wistar rats, weighting about 200–250g were used for this study. The rats were divided randomly into two groups namely healthy control (n=6) (Gr I) and disease control (Gr II) of 12 rats each. In the rats of group II, ascites was induced by Phenobarbital sodium @ 0.3g/L in the drinking water for first week (Abroades et al., 2006) followed by carbon tetrachloride (CCl₄) analar grade along with olive oil (1:1 v/v) @ 2 ml/ kg B.wt orally twice a week (Doi et al., 1991) for 11 weeks. The total experimental period was 12 weeks.

Clinical Signs and Body Weight

Experimental rats were observed closely for exhibition of any clinical and behavioral abnormality, and body weight was recorded at day 0, 2nd wk, 4th wk, 6th wk, 8th wk, 10th wk & 12th wks.

Samples Collection

Blood samples were collected at day 0, 4th, 8th & 12th wks for haemato-biochemical analysis to study the progressive changes in rat treated with CCl₄. Plasma/ Serum samples were separated from blood collected with/without anticoagulant at 3000xg for 10 min for various biochemical parameters estimation.

Haematology Profile

Haemoglobin and haematocrit, total erythrocyte counts (TEC), total leukocytes counts (TLC) were estimated by standard protocols.

Serum Biochemical Profile

ALT, AST, ALP, Serum bilirubin, total protein, albumin, sodium and potassium were measured by using commercial kits (Span Diagnostic, Surat India).

Sacrificing

Liver was collected after sacrificing animals at the end of 12 week as per Committee for the Purpose of Control and Supervision on Experiments CPCSE) on animals norms for gross and histopathological examination and oxidative stress index was performed in liver tissue.

Estimation of Antioxidant Level

Assays of Oxidative Stress Markers in the Liver Tissue Samples

Estimation of various oxidative stress marker parameters in the liver tissue was executed. A double beam UV-VIS spectrophotometer (UV 5704 SS, ECIL, India) was used for recording the absorbance of the test samples.

Preparation of Liver Homogenates

For oxidative stress indices, 500 mg of liver tissue was taken in 5 ml of ice-cold PBS (pH 7.4). Another 200 mg liver tissue was taken in 2 ml of 0.02 M EDTA in distilled water and used for estimation of (reduced glutathione) GSH. The homogenate (10%) prepared with homogenizer under ice-cold conditions were centrifuged 3000xg for 10 min and finally supernatant was stored at -20°C until assay.

Lipid Peroxidation (LPO) Assay

The concentration of Malonyldialdehyde (MDA), a reliable marker of lipid peroxidation, was estimated in tissue homogenate following the method suggested by Placer et al. (1966). Briefly, the reaction mixture consisted of 0.2 ml of 10% liver homogenate, 1.3 ml of 0.2 M Tris- 0.16 M KCl buffer (pH 7.4) and 1.5 ml of thiobarbituric acid reagent. The mixture was heated in boiling water bath for 10 min using glass beads as condenser. After cooling, 3ml of pyridine/n-butanol (15:1, v/v) and 1 ml of 1N sodium hydroxide (NaOH) were mixed by vigorous shaking. Optical density was measured spectrophotometrically at 532 nm against blank prepared by using distilled water. Lipid peroxidation was calculated on the basis of molar extinction coefficient of MDA-TBA complex at 548 nm i.e. 1.56×10^{-5} /mol/cm and expressed in terms of nmol of MDA/mg of protein.

Reduced Glutathione (GSH) Assay

The concentration of reduced glutathione in tissue homogenates was estimated by 5, 5-dithiobis-(2-nitrobenzoic acid) (DTNB) method as per the procedure of Sedlak and Lindsay (1968). Briefly, 1 ml of homogenate, 0.8 ml of water and 0.2 ml of 50% TCA solution were mixed and incubated at room temperature for 15 min. After incubation, the mixture was centrifuged at 3000xg for 15 min and 0.4 ml of supernatant was aspirated. Finally, 0.8 ml of 1M tris buffer and 0.2 ml of DTNB (0.01M) reagent was added and the optical density was measured spectrophotometrically at 412 nm within 5 min against blank prepared by using distilled water. Reduced glutathione concentration in the test sample was calculated by employing the molar extinction coefficient of DTNB-GSH conjugate (η mol/mg Hb), 13600/M/cm. Moles DTNB-GSH conjugate formed per g wet tissue (= [(OD/ ϵ) X (total vol. of reaction/ volume of taken sample) X DF X 1000]. Where ϵ is the molar extinction coefficient of DTNB-GSH conjugate at 412 nm.

Superoxide Dismutase (SOD) Assay

SOD activity in liver homogenate was measured by using nitro blue tetrazolium as a substrate after suitable dilution as per the method of Menami and Yoshikawa (1979). The increase in absorbance due to auto oxidation of pyrogallol was measured at 420 nm. One unit of SOD activity was defined as the amount of enzyme that inhibited auto-oxidation by 50% under the given experimental condition and the values were expressed as U/mg of protein.

Catalase (CAT) Assay

Catalase activity in liver homogenate was estimated by using H₂O₂ as a substrate (Bergmayer, 1983). Time (seconds) required for the fall in the initial absorbance by 0.05 was recorded. One unit of activity is equal to mmol of H₂O₂ degraded per minute and is expressed as U/mg of protein.

Gross Pathology of Liver

Liver of all the rats were examined at the end of experiment for any gross pathological changes (Runnels et al., 1965).

Histopathological Study

The liver tissues were fixed in 10% formalin and embedded with paraffin. The sections were cut and stained with hematoxylin and eosin.

Statistical Analysis

All data are expressed as means \pm SE unless otherwise specified. The analyses were performed with SPSS 16.0 (SPSS Inc., Chicago, IL, USA). The Student's t-test and ANOVA were used to analyze the *in-vitro* experimental study.

RESULTS

Clinical Signs and Body Weight

There were no mortality in rats exposed with CCl₄ and 8 (67%) rats exhibited mild abdominal distension on 11th and 12th weeks of experiments. Gr II rats showed dullness and decrease feed intake from 11th weeks onwards. Significantly decreased ($p < 0.05$) body weight were noticed in Gr II from 8th, whereas highly significant reduction ($p < 0.01$) in the body weight was observed on 12th week as compared to rats of Gr I. There was significant increase ($p < 0.05$) liver weight at 90th day in the rats of Gr II as compared to healthy ones (Table 1).

Table 1: Mean \pm SE of body weight and liver weight changes in rat treated with CCl₄

Parameters	Groups	
	Gr I	Gr II
day 0 b.wt (g)	218 \pm 4.25	213 \pm 13.07 ^{NS}
2 nd weeks b.wt (g)	224 \pm 6.14	209 \pm 11.84 ^{NS}
4 th weeks b.wt (g)	232 \pm 8.47	211 \pm 11.69 ^{NS}
6 th weeks b.wt (g)	247 \pm 8.37	205 \pm 12.32 ^{NS}
8 th weeks b.wt (g)	249 \pm 12.86	200 \pm 12.53*
10 th weeks b.wt (g)	253 \pm 12.87	177 \pm 12.59*
12 th weeks b.wt (g)	258 \pm 13.07	172 \pm 1.55**
Liver weight at 90 days (g)	7.46 \pm 0.47	9.51 \pm 0.56*
% liver weight	3.23 \pm 0.19	5.57 \pm 0.17**
% body weight	(+)14.44 \pm 5.54	(-) 23.86 \pm 4.0**

Means showing the same superscript in the row do not differ significantly; ** - Highly Significant. ($P \leq 0.01$); * - Significant ($P \leq 0.05$); NS - Not significant ($P > 0.05$); ** - Highly Significant. ($P \leq 0.01$), * - Significant ($P \leq 0.05$)

Hematology Profile

Highly significant ($p < 0.01$) decrease in hemoglobin was noticed on 12th week. Similarly, a significant ($p < 0.05$)

reduction in PCV and TEC values while TLC values of Gr II rats increased by the end of experimentation (Table 2).

Serum Biochemical Profile

There was highly significant ($p < 0.01$) decrease in total protein, albumin and A:G ratio whereas significant increase ($p < 0.05$) in globulin, AST, ALT, ALP and total bilirubin was noticed on 12th weeks of experiment in the rats of Gr II as compared to healthy control. Gradual significant reduction in the albumin level of Gr II rats was observed during the

experimentation. Values of A: G ratio in the rats of Gr II decreased significantly ($p < 0.05$). (Table 3)

Oxidative Stress Indices

Oxidative stress indices of this study reflects highly significant ($p < 0.01$) increase in the values of LPO (8.50±0.60 nmol MDA/mg protein) and decrease in CAT values in the rats of Gr II as compared to Gr I by the end of experimentation. Values of GSH and SOD decreased significantly ($p < 0.05$) in the rats of Gr II as compared to Gr I (Table 4).

Table 2: Mean ±SE of hematological changes in rat treated with CCL₄

Parameters	Gr I	Gr II			
		0 th week	4 th week	8 th week	12 th week
Hb (g/dl)	12.22±0.22 ^d	11.62±0.22 ^d	9.63±0.21 ^c	7.97±0.68 ^b	5.05±0.22 ^a
PCV (%)	37.50±0.62 ^c	35.67±0.95 ^c	28.67±0.72 ^b	25.67±3.13 ^b	18.67±0.65 ^a
TEC (x106 /µl)	4.10±0.06 ^b	4.03±0.06 ^b	2.66±0.18 ^a	2.60±0.17 ^a	2.18±0.06 ^a
TLC (x 103/ µl)	11.60±0.95 ^a	11.43±0.96 ^a	19.96±0.89 ^b	30.27±1.68 ^c	26.91±1.16 ^c

Means showing the same superscript in a row do not differ significantly; ** - Highly Significant. ($P \leq 0.01$); * - Significant ($P \leq 0.05$); NS - Not significant ($P > 0.05$); ** - Highly Significant. ($P \leq 0.01$), * - Significant ($P \leq 0.05$)

Parameters	Gr I	Gr II	4 th week	8 th week	12 th week
TP (g/dl)	6.51±0.05 ^b	6.40±0.11 ^b	6.22±0.07 ^b	5.88±0.20 ^{ab}	4.99±0.45 ^a
Albumin (g/dl)	4.48±0.09 ^d	4.53±0.09 ^d	3.37±0.19 ^c	2.78±0.14 ^b	1.91±0.08 ^a
Globulin (g/dl)	2.03±0.11 ^{ab}	1.87±0.11 ^a	2.84±0.19 ^{abc}	3.09±0.31 ^c	3.07±0.38 ^{bc}
A/G ratio	2.24±0.15 ^b	2.48±0.17 ^b	1.23±0.16 ^a	0.99±0.16 ^a	0.66±0.07 ^a
AST (IU/L)	55.53±3.70 ^a	96.88±17.53 ^{ab}	183.03±19.80 ^{bc}	196.10±20.80 ^c	200.0±31.19 ^c
ALT (IU/L)	57.94±9.96 ^a	58.91±9.34 ^a	103.54±5.41 ^b	125.43±5.35 ^b	133.60±8.14 ^b
ALP (IU/L)	60.31±2.22 ^a	70.90±3.80 ^a	185.91±2.33 ^b	197.91±4.03 ^b	229.73±9.20 ^c
T.bilirubin (mg/dl)	0.35±0.07 ^a	0.44±0.09 ^a	0.73±0.06 ^{ab}	0.89±0.14 ^b	1.07±0.04 ^b

Means showing the same superscript in a row do not differ significantly; ** - Highly Significant. ($P \leq 0.01$); * - Significant ($P \leq 0.05$); NS - Not significant ($P > 0.05$); ** - Highly Significant. ($P \leq 0.01$), * - Significant ($P \leq 0.05$)

Table 3: Mean ±SE of serum biochemical changes in rat treated with CCL₄

Groups	LPO	GSH	SOD	CAT
Gr I	3.28±0.29	6.67±0.59	5.86±0.1	4.81±0.34
Gr II	8.50±0.60 ^{**}	4.43±0.45 [*]	3.21±0.68 [*]	2.80±0.18 ^{**}

Table 4: Mean ±SE of liver tissue LPO, GSH, SOD and CAT activities in rat treated with CCL₄

Gr I- Healthy control, Gr II- Disease control CCL₄ @ 2ml/kg for 12 weeks; (LPO- nmol MDA/mg protein, GSH- µmoles/mg protein, SOD- U/mg protein and CAT- U/mg protein); Means showing the same superscript in the column do not differ significantly; ** - Highly Significant. ($P \leq 0.01$), * - Significant ($P \leq 0.05$), NS - Not significant ($P > 0.05$); ** - Highly Significant. ($P \leq 0.01$), * - Significant ($P \leq 0.05$)

Gross Pathology of Liver

Gross examination of liver of Gr I showed normal liver without ascites. Rats of Gr II revealed severe fibrosis with cirrhotic nodule by the end of the experiment (Figure 1). Ascites was noticed in 67% of the rats by the end of the experiment.

Histopathological Study

Gr I (Healthy group) showed normal architecture of hepatic lobes and failed to reveal any specific pathological changes and was graded 0 by histopathological score system (HPS). Section of rat liver in Gr II revealed perilobular fibrosis and fatty changes which led to the separation of the lobules (Figure 2).




Figure 1: Severe fibrosis with cirrhotic nodule and ascites




Figure 2: Revealed Perilobular fibrosis and fatty changes which led to the separation of the lobules 40X




Figure 3: Fibrous tissue reaction in portal triads and congestion of central vein 10X

Hepatocytes showed cytoplasmic vacuolation in variable sizes, increased fibrous tissue reaction in portal triads and congestion of central vein (Figure 3). Liver tissue of Gr II was graded 3 by HPS system.

DISCUSSION

Induction of Ascites in Rat with CCl₄ and Phenobarbital Sodium

The most validated cirrhosis model in the rat is produced using CCl₄ along with phenobarbital (Proctor and Chatamra, 1984). CCl₄ is one of the oldest and most widely used chemical agents for experimental induction of liver toxicity in laboratory animals (Domenicali et al., 2009). Chronic hepatotoxicity and cirrhosis in male sprague dawley rats could be produced by using CCl₄ @ 2 ml + 2 ml of olive oil per kg b.wt p.o twice a week for 12 wks (Doi et al., 1991). Continuous administration of CCl₄ induces chronic liver injury that leads to cirrhosis. Phenobarbital (0.3 g/L) was added to drinking water to increase the yield of liver cirrhosis, starting one week before first CCl₄ administration (Abralde et al., 2006). Rats developed micro nodular cirrhosis, portal hypertension, portal systemic shunting and hyper dynamic changes in the circulation (Vorobioff et al., 1983) 12 –15 weeks after CCl₄ administration. In the present study there were no mortality in rats exposed with CCl₄ and 67% of rats exhibited mild abdominal distension on 11th and 12th weeks and rats showed ascites during autopsy. These findings were similar with Domenicali et al. (2005 & 2009) who reported signs of hepatotoxicity using oral phenobarbital for first week followed by CCl₄ inhalation.

Clinical Signs and Body Weight

Nagano et al. (2007) recorded significant decrease in body weight and increase liver weight on administration of 18ppm CCl₄. In the present study also, highly significant (p<0.001) increase in percentage of liver weight and decrease in body weight were observed in CCl₄ treated rats. The increase in liver weight could be attributed to the accumulation of fat (Reddy et al., 2010).

Haematology Profile

Significant reduction was recorded in hemoglobin concentration, PCV and TEC values while TLC values of Gr II rats exhibited an increase, indicating the presences of anaemia and leukocytosis. This anaemia and leukocytosis may be due to the direct effect of toxin on the haematopoietic system (Parent– Massin, 2004). Significant decrease in Hb and haematocrit values were noticed in male

and female rats exposed to CCl₄ @ 90 ppm (Nagano et al., 2007) possibly due to the toxic effect CCl₄ on the hematopoietic system.

Serum Biochemical Profile

Hypoalbuminemia and hypoproteinemia are the useful index for determining the severity of hepatocellular damage (Aniya et al., 2005). Increased liver enzymes in CCl₄ treated rats might be due to release of cytosolic enzyme into blood stream due to liver cell plasma membrane damage and loss of functional integrity of cell membrane in liver (Kazeem, et al., 2011). The increased levels of serum ALT and AST are indicative of cellular leakage and loss of functional integrity of cell membrane in the liver. Hepatocellular necrosis leads to elevation of the serum marker enzymes, released from the liver into blood like increased levels of serum ALT, AST, ALP and bilirubin are conventional indicators of liver injury which is supporting the present findings of Shenoy et al. (2002); Achliya et al. (2003).

Oxidative Stress Indices

In present investigation, significant (P<0.01) elevation of lipid peroxidation in the liver of rats receiving CCl₄ (Gr II) reflects membrane damage as alteration in its structure and function. The hepatotoxic effect of CCl₄ is largely due to its active metabolite, trichloro methyl radical. The activated radicals bind covalently to the macromolecules and induce peroxidative degradation of membrane lipids of endoplasmic reticulum (ER) that is rich in polyunsaturated fatty acids (Hye, 2002). The increase in malondialdehyde levels in liver suggested enhanced lipid peroxidation leading to tissue damage and failure of antioxidant defense mechanisms to prevent the formation of excessive free radicals (Shenoy et al., 2002). Significantly (P<0.01) reduced activities of SOD, Catalase and GSH in group receiving CCl₄ (Gr II) point out the hepatic damage (Kazeem et al., 2011). Regarding non-enzymatic antioxidants, GSH has been considered as a critical determinant of tissue susceptibility to oxidative damage and the depletion of hepatic GSH has been associated with an enhanced toxicity to chemicals, including CCl₄ (Hewawasan et al., 2003). These reactive oxygen species can induce degenerative changes by oxidation of protein, peroxidation of lipids and damage to nucleic acids (Doelman and Bast, 1990). One of the principal causes of CCl₄ induced liver injury is formation of lipid peroxides by free radical derivatives of CCl₄ (CCl₃). CCl₄ induced adverse changes were evident from the decreased hepatic antioxidant enzyme ability viz., SOD, GPX followed by GSH of the present study. The body has an effective

defence mechanism to prevent and neutralize the free radical-induced damage. This has been accomplished by a set of endogenous antioxidant enzymes such as SOD, catalase and GPX. These enzymes constitute a mutually supportive team of defense against ROS (Babe and Panemangalore, 2003). In CCl₄ induced hepatotoxicity, the balance between reactive oxygen species (ROS) production and the antioxidant defense may be lost resulting in oxidative stress, which through a series of events deregulates the cellular functions leading to hepatic necrosis.

Gross Pathology of Liver

Gross examination of CCl₄ treated (Gr II) rats liver revealed severe fibrosis with nodular cirrhosis with ascites in 67% rats by the end of experimentation. The results conformed to the observations of Vorobioff et al. (1983) who reported micro nodular cirrhosis, portal hypertension, portal systemic shunting and hyper dynamic changes in the circulation in 12–15 wks after CCl₄ administration. Domenicali et al. (2005 and 2009) also reported the development of ascites between 11th and 15th weeks with oral phenobarbital for first week and followed by CCl₄ inhalation in rat.

Histopathological Study

Hepatic damage produced by CCl₄ was characterized by fatty changes, centrilobular necrosis, hydropic degeneration and cirrhosis. Doi et al. (1991) and Huang et al. (2006) also reported similar changes following CCl₄ administration in rats.

CONCLUSION

Oral administration of Phenobarbital sodium followed by Carbon tetrachloride (CCl₄) could be used for induction of liver cirrhosis with ascites in wistar rats.

ACKNOWLEDGEMENTS

Authors are extremely grateful to the Director, Indian Veterinary Research Institute, Izatnagar for providing all facilities for the study

REFERENCES

Abraldes JG, Pasarin M, Garcia-Pagan JC (2006). Animal model of Portal hyper-tension. *World J. Gastroenterol.* 12 (41): 6577 – 6584.
Aniya Y, Koyama T, Miyagi C, Miyahira M, Inomata C, Kinoshita S, Ichiba T (2005). Free radical scavenging activity and hepatoprotective actions of medicinal herb, *Crassocephalum crepidioides* from the Okinawa islands. *Biol. Pharm. Bull.* 28: 19 – 23.
Babe FN, Panemangalore M (2003). Exposer to low doses of endosufan and chlor-pyriphos modifies endogenous antioxidants in tissues of rats. *J. Environ. Sci. Health.* 38:349–363.
Bergmayer HU (1983). UV method of catalase assay. In: *Methods of Enzymatic Analysis*, Deer Field Beach, Florida, 3: 273.
Doelman CJA, Bast A (1990). Oxygen radicals in lung pathology. *Biol. Med.* 9: 381 – 400.

Doi K, Kurab S, Shimazu N, Inagaki M (1991). Systemic histopathology of rats with CCl₄- induced hepatic cirrhosis. *Lab. Anim.* 25: 21 – 25.
Domenicali M, Caraceni P, Giannone F, Baldassarre M, Lucchetti G, Quarta C, Patti C, Catani L, Nanni C, Lemoli RM, Bernardi M (2009). A novel model of CCl₄-induced cirrhosis with ascites in the mouse. *J. Hepatol.* 51: 991 – 999.
Domenicali M, Caraceni P, Principe A, Pertosa AM, Ros J, Chicco P, Trevisani F, Jimenez M, Bernardi M (2005). A novel sodium overload test predicting ascites decompensation in rats with CCl₄-induced cirrhosis. *J. Hepatol.* 43: 92 – 97.
Hewawasan RP, Jayatilaka KAPW, Pathirana C, Mudduwa LKB (2003). Protective effect of *Asteracantha longifolia* extracts mouse liver injury induced by carbon tetrachloride and paracetamol. *J. Pharmacol.* 55: 1413 – 1418.
Huang YH, Mei-Na Shi, Wei-Da Zheng, Li-Juan Zhang, Zhi-Xin Chen, Xiao-Zhong Wang (2006). Therapeutic effect of interleukin-10 on CCl₄-induced hepatic fibrosis in rats. *World J. Gastroenterol.* 12(9): 1386 – 1391.
Hye GJ (2002). Hepatoprotective effect of 18b- Glycyrrhetic acid on carbon tetrachloride-induced liver injury: inhibition of cytochrome P4502E1 expression. *Pharmacol. Res.* 46: 221 – 227.
Kazeem MI, Bankole HA, Fatai AA (2011). Protective effect of ginger in normal and carbon-tetrachloride- induced hepatotoxic rats. *Anal. Biol. Res.* 2 (1): 1 – 8.
Menami M, Yoshikawa H (1979). Simplified assay method of superoxide dismutase activity of clinical use. *Clin. Chem. Acta.* 92: 337 – 342.
Mullen KD, McCullough AJ (1989). Problems with animal models of chronic liver disease: suggestions for improvement in standardization. *Hepatol.* 9: 500 – 503.
Nagano K, Umeda Y, Saito M, Nishizawa T, Ikawa N, Arito H, Yamamoto S, Fukushima, S (2007). Thirteen-week inhalation toxicity of carbon tetrachloride in rats and mice. *J. Occup. Health.* 49(4): 249 – 259.
Parent- Massin D (2004). Haematotoxicity of trichothecenes. *Toxicol. Lett.* 153 (1): 75 – 81.
Parola M, Robino G (2001). Oxidative stress-related molecules and liver fibrosis. *J. Hepatol.* 35: 297 – 306.
Placer ZA, Cushman LL, Johnson BT (1966). Estimation of product of lipid per-oxidation (malonyl dialdehyde) in biochemical systems. *Anal. Biochem.* 16: 359 – 364.
Poli G (2000). Pathogenesis of liver fibrosis: role of oxidative stress. *Mol. Aspects Med.* 21: 49 – 98.
Proctor E, Chatamra K (1984). Standardized micronodular cirrhosis in the rat. *Eur. Surg. Res.* 16: 182 – 186.
Reddy J, Ganasekaran D, Vijay D, Ranganathan TV (2010). Studies on hepatoprotective activity of traditional ayurvedic formulation VIDAKANA CHOORNAM against CCl₄ induced hepatotoxicity in albino rat. *Int. J. Pharm. Anal.* 2(2): 5 – 16.
Runnels RA, Monlux WS, Monlux AW (1965). Principles of Veterinary Pathology. 7th edn., Scientific Book Agency, Calcutta.
Runyon BA (2004). Management of adult patients with ascites due to cirrhosis. *Hepatol.* 39: 841 – 854.
Sedlak J, Lindsay RH (1968). Estimation of total protein bound and non protein sul-phydryl groups in tissues with Elman,s reagent. *Anal. Biochem.* 25: 192 – 205.
Shenoy KA, Somayaji SN, Bairy KL (2002). Evaluation of hepatoprotective activity of *Gingobiloba* in rats. *Indian J. Pharmacol.* 46(2): 167 – 174.
Vorobioff J, Bredfeldt JE, Groszmann RJ (1983). Hyper dynamic circulation in portalhypertensive rat model: a primary factor for maintenance of chronic portal hyper-tension. *Am. J. Physiol.* 244: G52 – G57.
Ward FM, Daly MJ (1999). Hepatic Disease. In: *Clinical Pharmacy and Therapeutics*, Walker R and Edwards C (Ed), Churchill Livingstone, New York, 195 – 212.
Williams T, Burk RF (1990). Carbon tetrachloride hepatotoxicity: an example of free radical-mediated injury. *Semin. Liver Dis.* 10, 279 – 284.